Physician profile
Ferris E George
NPI 1467474080
$16,075.20
in general payments reported to CMS, 2019-2025
40 companies · $1,940 in 2025
The $1,940 reported for 2025 was more than what 83% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,529 · 2020: $1,853 · 2021: $2,315 · 2022: $2,587 · 2023: $3,495 · 2024: $2,356 · 2025: $1,940.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,776 · Travel and Lodging: $1,015.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,775.97 |
| Travel and Lodging | $1,014.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $5,028.36 | 2021-2025 | Onyx Frontier, Micra, Cobalt Dr Mri Surescan |
| Medtronic Vascular, INC. | $1,437.75 | 2019-2020 | |
| Boston Scientific Corporation | $1,339.75 | 2019-2024 | Hornet 10, Resonate El Icd Vr, Avvigo Guidance System |
| Shockwave Medical, INC | $1,263.85 | 2022-2024 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter, Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter, Shockwave Intravascular Lithotripsy (Ivl) System With The Shockwave C2+ Coronary |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,156.59 | 2022-2025 | Jardiance |
| Abiomed | $850.24 | 2020-2025 | Impella |
| Amgen INC. | $529.83 | 2019-2024 | Repatha |
| Abbott Laboratories | $487.36 | 2019-2024 | Mitraclip, Coroflow, Pressurewire |
| Novartis Pharmaceuticals Corporation | $418.09 | 2020-2024 | |
| Pfizer INC. | $384.47 | 2019-2024 | |
| Astrazeneca Pharmaceuticals Lp | $355.80 | 2019-2024 | Farxiga |
| Biotronik INC. | $299.61 | 2020-2022 | |
| E.R. Squibb & Sons, L.L.C. | $296.43 | 2019-2023 | Eliquis, Camzyos |
| Cvrx, INC. | $292.70 | 2021-2023 | Barostim Neo System |
| Merck Sharp & Dohme LLC | $279.42 | 2021-2024 | Verquvo |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $217.14 | 2019-2024 | Xarelto |
| Astellas Pharma US INC | $198.00 | 2021 | |
| Sanofi-Aventis U.S. LLC | $152.08 | 2019 | |
| Acist Medical Systems, INC. | $144.36 | 2019-2021 | |
| Teleflex LLC | $115.01 | 2019-2024 | Vascband, Trapliner |
| Penumbra, INC. | $111.99 | 2022-2024 | Indigo System |
| Chiesi USA, INC. | $105.05 | 2019-2022 | |
| Ge Healthcare | $103.45 | 2019-2024 | |
| Esperion Therapeutics, INC. | $97.22 | 2020-2023 | Nexletol |
| Cardiovascular Systems INC. | $72.13 | 2020-2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $61.56 | 2019-2023 | Lifevest |
| Lexicon Pharmaceuticals, INC. | $59.90 | 2023-2024 | Inpefa |
| Cardiva Medical, INC. | $56.39 | 2022 | |
| Getinge USA Sales, LLC | $29.87 | 2019-2020 | |
| Zoll Circulation INC | $26.32 | 2022 | |
| Celonova Biosciences, INC. | $23.28 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $21.85 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $20.26 | 2022 | |
| Elutia, INC. | $13.24 | 2019 | |
| Bardy Diagnostics, INC. | $13.00 | 2021 | |
| Terumo Medical Corporation | $12.85 | 2023 | Glidewire |
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ferris George listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.